Abstract
Overview
Introduction
The autoimmune disease market will be rapidly growing due to a high number of
competitive brands currently on the market and a full pipeline. Company
strategies include expanding the treatment algorithm by pursuing approval for
' early' disease stages, launching easy-to-use devices to make up for downsides
of injectable drugs, and developing fully human monoclonal antibodies as
follow-on products.
Scope
- Indication based forecasts for the top autoimmune brands and significant
pipeline drugs
- Assessment of indication-specific drivers and resistors likely to impact
the market
- Future market outlook for individual products taking into account key
market events, and competitor launch dates
- Market overview by indication, mechanism of action and geographical area
with value analysis of clinical and commercial factors underlying performance
Report Highlights
In 2006, the TNF-inhibitors were by far the highest selling mechanism of
action in the autoimmune market, across all seven major markets. This group of
products was very popular in the US especially, with sales of $6.5 billion
accounting for 66% of the market.
In the US, rheumatoid arthritis and multiple sclerosis both had a large share
of the sales, 44% ($4.4 billion) and 32% (almost $3.2 billion), respectively.
Psoriasis/psoriatic arthritis sales and Crohn' s disease sales were lower
compared to the top two indications, with sales of $1.2 billion (12%) and
$722m (7%), respectively.
Remicade was the second highest-selling drug in the seven major markets of the
brands evaluated in this report with sales of $3,130m in 2006. Datamonitor
expects this to decrease over the next 10 years mainly due to the launch of
follow-on humanized TNF-inhibitor golimumab, which is forecast to take the
majority of its share from Remicade.
Reasons to Purchase
- Identify key opportunities and threats that will impact the use and uptake
of new and existing products
- Quantify the future size and scope of the autoimmune market and predict
the future performance of key compounds
- Understand and capitalize on clinical unmet needs in the market, either
through lifecycle management of marketed drugs or new product development
| 
View Cart
